Ann: Investor Update Webinar, page-22

That's a big one. It seems that everyone who wants to be long has their positions already (and for some time now), barring small top-ups, which look to be more infrequent.

Funding is the elephant in the room. Once that's in place/addressed, the subsequent expected announcements like FDA approval, $6.3m revenues locked in, US listing update, product release dates, manufacturing updates, etc. in my opinion will bring in new investor funds and hopefully set a new base much higher than we are for the price. At the moment, the chart looks quite anaemic. A decent amount of churn to get through to sustain the price above 50cents.

By all accounts, we should be very close (<2 months) to gaining full clarity on funding and getting updates on a number of other fronts. So not long to wait now.

IMO DYOR

Cheers.